SELPLG and medullary thyroid gland carcinoma: There is still a matter of debate: if CLA is more severe in MEN2 versus non-MEN2 subjects; if MTC displays a more severe outcome in CLA-positive versus CLA-negative patients; if there is a distinct risk of non-MTC MEN2 components other than the indications provided by the mutation map in CLA-positive individuals.